Prostate Cancer Therapy Using Docetaxel and Formononetin Combination: Hyaluronic Acid and Epidermal Growth Factor Receptor Targeted Peptide Dual Ligands Modified Binary Nanoparticles to Facilitate the in vivo Anti-Tumor Activity
Zhaoqiang Dong,Yuzhen Wang,Jing Guo,Chuan Tian,Wengu Pan,Hongwei Wang,Jieke Yan
DOI: https://doi.org/10.2147/DDDT.S366622
2022-08-12
Abstract:Zhaoqiang Dong, 1 Yuzhen Wang, 2 Jing Guo, 3 Chuan Tian, 4 Wengu Pan, 4 Hongwei Wang, 4 Jieke Yan 4 1 Department of Cardiology, The Second Hospital of Shandong University, Ji'nan, 250033, People's Republic of China; 2 Clinical Department, Jinan Vocation College of Nursing, Ji'nan, 250033, People's Republic of China; 3 Department of Gynaecology, The Second Hospital of Shandong University, Ji'nan, 250033, People's Republic of China; 4 Department of Renal Transplantation, The Second Hospital of Shandong University, Ji'nan, 250033, People's Republic of China Correspondence: Jieke Yan, Department of Renal transplantation, The Second Hospital of Shandong University, No. 247 Beiyuan Street, Ji'nan, 250355, People's Republic of China, Email Objective: To evaluate the prostate cancer therapy efficiency of the synergistic combination docetaxel (DTX) and formononetin (FMN) in one nano-sized drug delivery system. Hyaluronic acid (HA) and epidermal growth factor receptor-targeted peptide (GE11) dual ligands were applied to modify the nano-systems. Methods: In this study, GE11-modified nanoparticles (GE-NPs) were applied for the loading of DTX, and HA-decorated NPs (HA-NPs) were used to encapsulate FMN. HA and GE11 dual ligand-modified binary nanoparticles (HAGE-DTX/FMN-NPs) were constructed by the self-assembling of GE-NPs and HA-NPs. The anti-PCa ability of the system was evaluated in vitro on PC-3 human prostate carcinoma cells (PC3 cells) and in vivo on PC3 tumor-bearing mice in comparison with single NPs and free drugs formulations. Results: HA/GE-DTX/FMN-NPs were nano-sized particles with smaller particles coating on the inner core and achieved a size of 189.5 nm. HA/GE-DTX/FMN-NPs showed a cellular uptake efficiency of 59.6%, and a more efficient inhibition effect on PC3 cells compared with single ligand-modified NPs and free drugs. HA/GE-DTX/FMN-NPs showed significantly higher tumor inhibition efficiency than their single drug-loaded counterparts and free drugs. Conclusion: HA/GE-DTX/FMN-NPs have a synergistic anti-tumor effect and also could the reduce unexpected side effects during the cancer therapy. It could be used as a promising anti-PCa system. Keywords: prostate cancer, docetaxel, formononetin, hyaluronic acid, epidermal growth factor receptor, binary nanoparticles Prostate cancer (PCa) is the second most commonly diagnosed cancer (20% of male new cancer cases) and the fifth leading cause of cancer death in males (9.8% of male cancer deaths). 1,2 Androgen-deprivation therapy (ADT) is the initial treatment of metastatic PCa involving surgical castration or medical castration. 3,4 However, metastatic PCa will inevitably progress to metastatic castration-resistant prostate cancer (mCRPC). 5 Based on several phase III clinical trials, every-3-week docetaxel with concurrent steroid is the preferred first-line chemotherapy treatment for men with symptomatic mCRPC. 4,6,7 Docetaxel (DTX), an approved antineoplastic agent, can enhance tubulin polymerization and inhibit microtubule depolymerization, which results in the inhibition of mitosis in cells and achieves anti-tumor effect. However, due to its drug resistance and insolubility (4.93 μg/mL in water), combination therapy and diverse anti-cancer nano-drug delivery systems were engineered for inhibition of aforementioned drawbacks. 8–10 The synergy of action mechanism is the prerequisite of combination therapy, and the combination of DTX and Chinese traditional medicine has become the focus of research, such as DTX and Fuzheng Yiliu decoction whose principal component is formononetin (FMN). 11–14 FMN, a methoxylated isoflavone [7-hydroxy-3-(4-methoxypheny)-4H-1-benzopyran-4-one], can be mainly extracted from red clover ( Trifolium pratense ) and the Chinese medicinal plant Astragalus membranaceus . 15 FMN is insoluble in water and has been used as one of the fundamental herbs for the treatment of cancer in China. 14 The therapeutic prospect of FMN in treating prostate cancer, especially for castration-resistant prostate cancer, has been evidenced in several cell culture systems and human xenograft mouse models. 14,16 The mechanism of FMN, which induced cytotoxicity in prostate cancer cells, contains two factions, apoptosis and G1 cell cycle arrest. 17 Specifically, apoptosis is due to upregulation of dexamethasone-induced retrovirus-associated DNA sequences (Ras)-related protein 1 (RASD1), Bcl-2-associated protein (Bax), caspase-3, and PARP (poly-ADP ribose polymerase); reduction of B-cell lymphoma 2 (Bcl-2) levels; inhibition of insulin-like growth facto -Abstract Truncated-